Items where authors include "Deodhar, A"
Up a levelArticle
McGonagle, D, McInnes, IB, Deodhar, A et al. (10 more authors) (2023) Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology, 5 (4). pp. 227-240. ISSN 2578-5745
Orbai, A-M, Coates, LC, Deodhar, A et al. (10 more authors) (2022) Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. The Patient: Patient Centered Outcomes Research, 15 (6). pp. 657-668. ISSN 1178-1653
Gladman, DD, Mease, PJ, Bird, P et al. (14 more authors) (2022) Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials, 23 (1). 743. ISSN 1745-6215
Kvien, TK, Conaghan, PG orcid.org/0000-0002-3478-5665, Gossec, L et al. (8 more authors) (2022) Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long‐term Results of Two Phase III Randomized Controlled Trials. Arthritis Care & Research, 74 (5). pp. 759-767. ISSN 2151-464X
Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, DD et al. (14 more authors) (2021) Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. The Lancet Rheumatology, 3 (10). e715-e723. ISSN 2665-9913
Rahman, P, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (10 more authors) (2021) Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 23 (1). 190. ISSN 1478-6354
Deodhar, A, Strand, V, Conaghan, P orcid.org/0000-0002-3478-5665 et al. (6 more authors) (2020) Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study. BMC Rheumatology, 4 (1). 19. ISSN 2520-1026
Strand, V, Deodhar, A, Alten, R et al. (6 more authors) (2020) Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings. JCR: Journal of Clinical Rheumatology. ISSN 1076-1608
Mease, PJ, Gladman, DD, Deodhar, A et al. (9 more authors) (2020) Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open, 6 (2). e001217. ISSN 2056-5933
Conaghan, PG orcid.org/0000-0002-3478-5665, Alten, R, Deodhar, A et al. (6 more authors) (2020) Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open, 6 (2). e001240. ISSN 2056-5933
Deodhar, A, Helliwell, PS, Boehncke, W-H et al. (9 more authors) (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 395 (10230). pp. 1115-1125. ISSN 0140-6736
Alten, R, Conaghan, PG orcid.org/0000-0002-3478-5665, Strand, V et al. (6 more authors) (2019) Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clinical Rheumatology, 38 (6). pp. 1615-1626. ISSN 0770-3198
Braun, J, Baraliakos, X, Deodhar, A et al. (5 more authors) (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford, England), 58 (5). pp. 859-868. ISSN 1462-0324
Deodhar, A, Conaghan, P orcid.org/0000-0002-3478-5665, Kvien, T et al. (6 more authors) (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clinical and Experimental Rheumatology, 37 (2). 12626. 0260-0269. ISSN 0392-856X
Braun, J, Baraliakos, X, Deodhar, A et al. (8 more authors) (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases, 76 (6). pp. 1070-1077. ISSN 0003-4967
Peterfy, C, Strand, V, Tian, L et al. (9 more authors) (2017) Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. Annals of the Rheumatic Diseases, 76 (6). pp. 992-997. ISSN 0003-4967
Moltó, A, Etcheto, A, Van der Heijde, D et al. (23 more authors) (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 75 (6). pp. 1016-1023. ISSN 0003-4967
Baeten, D, Sieper, J, Braun, J et al. (10 more authors) (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine, 373 (26). pp. 2534-2548. ISSN 0028-4793
Conference or Workshop Item
Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.
Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program. In: ACR Convergence 2021, 05-09 Nov 2021, Online.
Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.
Orbai, A-M, Coates, L, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.
Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Orbai, AM, Coates, LC, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 Discover-1 Trial. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105, Deodhar, A et al. (6 more authors) (2021) In Phase-3 Trials Discover 1 & 2, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20). In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (12 more authors) (2021) Efficacy of Guselkumab on Axial-Related Endpoints in Patients with Active Psoriatic Arthritis with Imaging-Confirmed Sacroiliitis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.
Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (15 more authors) (2020) Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies. In: 37º Congresso Brasileiro de Reumatologia, 19-22 Nov 2020, Virtual.
Ritchlin, C, Deodhar, A, Boehncke, W-H et al. (10 more authors) (2020) Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naive Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105, Boehncke, W-H et al. (8 more authors) (2020) Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Orbai, A-M, Coates, L, Deodhar, A et al. (8 more authors) (2020) Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Helliwell, P orcid.org/0000-0002-4155-9105, Mease, P, Kavanaugh, A et al. (9 more authors) (2020) What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Orbai, AM, Coates, LC, Deodhar, A et al. (8 more authors) (2020) AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. In: EULAR 2020, 03-06 Jun 2020, Online.
Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.
Ritchlin, CT, Helliwell, P, Boehncke, WH et al. (8 more authors) (2020) SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. In: EULAR 2020, 03-06 Jun 2020, Online.
Helliwell, P, Rahman, P, Deodhar, A et al. (6 more authors) (2020) SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2. In: EULAR 2020, 03-06 Jun 2020, Online.
Deodhar, A, Helliwell, P, Boencke, W-H et al. (8 more authors) (2020) GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNF alpha INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. In: 22nd PANLAR Congress, 12-15 Aug 2020, Miami, Florida, USA.
Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.
Deodhar, A, Kirkham, B, Rahman, P et al. (6 more authors) (2020) P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.
Deodhar, A, Helliwell, P, Boencke, W-H et al. (7 more authors) (2019) Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, GA, USA.
Gladman, D, Boehncke, W-H, Gottlieb, AB et al. (7 more authors) (2019) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.
Helliwell, P, Gottlieb, AB, Deodhar, A et al. (7 more authors) (2019) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.
Proceedings Paper
Helliwell, P, Deodhar, A, Gottlieb, AB et al. (7 more authors) (2019) Comparing Composite Measures of Disease Activity in Psoriatic Arthritis: Results From a Randomized Phase 2 Trial with Guselkumab. In: Annals of the Rheumatic Diseases. EULAR 2019: Annual European Congress of Rheumatology, 12-15 Jun 2019, Madrid, Spain. BMJ Publishing Group , p. 1843.